Lead Product(s) : Pidnarulex,Cemiplimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Senhwa Biosciences’ Pidnarulex Joins Forces with Global PD-1 Leaders
Details : The company’s novel investigational drug, CX-5461 (pidnarulex), will be evaluated in combination with the approved PD-1 inhibitor Libtayo (cemiplimab), provided by Sanofi and Regeneron.
Product Name : CX-5461
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : Pidnarulex,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Issues Approval for Pidnarulex Study in Advanced Solid Tumors
Details : Pidnarulex (CX-5461) is a first-in-class small-molecule designed to stabilize G4 structures, it induces DNA damage and promotes cancer cell death, holding a great potential for various cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 14, 2024
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Submits IND for Pidnarulex Study in Advanced Solid Tumors Sponsored by NCI
Details : (CX-5461 (pidnarulex), is a first-in-class small-molecule designed to stabilize G-quadruplex structures, which is being evaluated for the treatment of Solid Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-5461 (Pidnarulex) demonstrated clinically significant and persist benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations, and who had been exposed to platinum and other chemotherapeutics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pidnarulex synthetically derived small molecule in combination with Talazoparib (PARP inhibitor), potential therapy in patients with metastatic castration-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : Pidnarulex,Talazoparib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Peter MacCallum Cancer Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a previous phase 1 trial, Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations and that were also resistant to platinum and other chemotherapeutics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the CCTG Trial, CX-5461 demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable